- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01525082
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
- Estimate if the combination of capecitabine and temozolomide with bevacizumab for metastatic or unresectable neuroendocrine tumors will improve response rate (RR) by 62% over historical controls (null RR of 40% to true RR 65%).
- Assess the toxicities using Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
SECONDARY OBJECTIVES:
- Evaluate progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier analysis.
- Assess O6-methyl guanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) at baseline by central pathology (path) review.
- Assess serum hormone marker levels.
- Evaluate computed tomography (CT) Perfusion as a tool to predict early therapeutic response. (Optional)
- Bank serum for future correlative analyses.
OUTLINE:
Patients receive bevacizumab intravenously (IV) over 30 to 90 minutes on days 1 and 15, capecitabine orally (PO) twice daily (BID) on days 1 to 14, and temozolomide PO once daily (QD) on days 10 to 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity, with assessment for treatment effect every 3 cycles.
After completion of study treatment, patients are followed up patients are followed long-term for survival.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA
- Histologically-confirmed pancreatic neuroendocrine tumors that are moderately- or well-differentiated
- Metastatic or unresectable disease
- If prior surgical resection > 5 years before the development of metastatic disease, a separate (recent) histological or cytological confirmation of metastatic disease is required
- If there is substantial clinical ambiguity regarding the nature or source of apparent metastases, clinicians should consider biopsy of lesions to establish diagnosis of metastatic disease
- The site of previous radiotherapy, if the only site of disease, has evidence of progressive disease
- If prior sunitinib and everolimus has been administered, a 2-week wash-out period is required prior to 1st dose on this study
- If prior liver-directed therapies (ie, chemoembolization, radioembolization), target lesions in the liver have demonstrated growth since the liver-directed treatment
- If prior peptide receptor radionuclide therapy (PRRT), target lesions in the liver have demonstrated growth since the liver-directed treatment
- Low-dose aspirin (≤ 325 mg/d) may be continued in subjects at higher risk for arterial thromboembolic disease.
- Primary or metastatic tumor lesion measurable in at least 1 dimension, within 4 weeks prior to entry of study.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- ≥ 18 years of age.
- Laboratory values as follows, ≤ 2 weeks prior to randomization:
- Absolute neutrophil count (ANC) ≥ 1.5 x 10e9/L (≥ 1500/mm³)
- Platelets (PLT) ≥ 100 x 10e9/L (≥ 100,000/mm³)
- Hemoglobin (Hgb) ≥ 9 g/dL
- Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
- Serum bilirubin ≤ 1.5 x ULN
- Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) ≤ 3.0 x ULN (≤ 5.0 x ULN if liver metastases present). Note: endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous stenting may be used to normalize the liver function tests
- Urine dipstick or urinalysis for protein, value must be 0, trace, or 1+ protein to enroll. EXCEPTION: if ≥ 2+ must check 24-hour urine protein and must be < 1 g
- Life expectancy ≥ 12 weeks
- Ability to give written informed consent according to local guidelines
- If any prior therapy-related toxicities, must have recovered from all
EXCLUSION CRITERIA Disease-Specific Exclusions
- Prior bevacizumab; fluoropyrimidines (eg, capecitabine or 5-fluorouracil, 5FU); or temozolomide
- Poorly-differentiated or high-grade pancreatic neuroendocrine tumors
- Prior full field radiotherapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior to enrollment
- Diagnosis of another malignancy, unless > 3 years earlier and has been disease-free for > 6 months following the completion of curative intent therapy, specific eligibility exceptions as follows:
- Curatively-resected non-melanomatous skin cancer
- Curatively-treated cervical carcinoma in situ
- Organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values, if hormonal therapy has been initiated or a radical prostatectomy has been performed
- Other primary solid tumor curatively treated with no known active disease present and no treatment administered for > 3 years
- Concurrent use of other investigational agents and patients who have received investigational drugs ≤ 4 weeks prior to enrollment
- Known hypersensitivity to capecitabine, temozolomide, or any component of the formulation
- Known deficiency of dihydropyrimidine dehydrogenase Bevacizumab-specific Exclusions
- Inadequately-controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg)
- Prior history of hypertensive crisis or hypertensive encephalopathy
- New York Heart Association (NYHA) Grade II or greater congestive heart failure
- History of myocardial infarction or unstable angina within 6 months prior to Day 1
- History of stroke or transient ischemic attack within 6 months prior to Day 1
- Known central nervous system (CNS) metastases
- Significant vascular disease (eg, aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1
- History of hemoptysis (≥ ½ teaspoon of bright red blood per episode) within 1 month prior to Day 1
- Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study
- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
- History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1
- Serious, non-healing wound, active ulcer, or untreated bone fracture
- Known hypersensitivity to any component of bevacizumab General Medical Exclusions
- Inability to comply with study and/or follow-up procedures
- Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study
- Pregnant or lactating/breast feeding
- Lack of effective contraception men or women of child-bearing potential
- Uncontrolled systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
- Known history of HIV, HBV, or HCV
- Current, ongoing treatment with full-dose warfarin. However, patients may be on stable doses of a low-molecular weight heparin are allowed [eg, (enoxaparin (Lovenox)].
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bevacizumab + Capecitabine + Temozolomide
Cycles repeat every 28 days until disease progression, unacceptable toxicity, or withdrawal.
|
Capecitabine by mouth twice daily on Days 1 to 14
Other Names:
Temozolomide by mouth daily on Days 10 to 14
Other Names:
Bevacizumab IV over 30 to 90 minutes on Days 1 & 15
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiographic Response (RR)
Time Frame: 18 months
|
Tumor response to treatment with the combination of capecitabine & temozolomide plus bevacizumab in patients with metastatic or unresectable pancreatic neuroendocrine tumors was assessed per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) for target lesions. Response is defined as:
The outcome is reported as the number of participants who between 3 and 18 months after treatment initiation achieve CR, PR, or clinical response (PR + CR), each a number without dispersion. |
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-related Toxicity
Time Frame: 18 months
|
Patients will be monitored for hematologic (blood and lymphatic), gastrointestinal (stomach and gut), renal (kidney), liver (metabolic), neurological, and systemic (constitutional) toxicities (treatment-related adverse events).
Toxicity events occurring during treatment will be tabulated for each indicated organ system, and listed separated for serious and non-serious events, with the toxicity attribution indicated.
The outcome is reported as the number of events, a number without dispersion.
|
18 months
|
Progression-free Survival (PFS)
Time Frame: 82 months
|
Progression-free survival (PFS) means the length of time that participants survive without disease (tumor) progression, and was assessed using Kaplan-Meier analysis.
The outcome is given as the mean in months with standard error of the mean.
|
82 months
|
Overall Survival (OS)
Time Frame: 82 mo
|
Time from the date of enrollment to the date of death due to any cause or the last date the patient was known to be alive (censored observation) at the date of data cutoff for the final analysis. The results will be reported as median in months The length of overall survival (OS) of participants was assessed by Kaplan-Meier analysis. The outcome is given as the median in months with full range. |
82 mo
|
O6-methylguanine DNA Methyltransferase (MGMT) Status by Immunohistochemistry (IHC)
Time Frame: 18 months
|
O6-alkylguanine DNA alkyltransferase is a protein that in humans is encoded by the gene "O6-methylguanine DNA methyltransferase" (MGMT). Deficiency of the gene product, ie, the protein, is refereed to as "MGMT deficiency," and is thought to be predictive of response to temozolomide and is more often associated with pancreatic NETs. MGMT status in pre-treatment biopsy specimens was to be assessed by immuno-histochemistry (IHC), and associated to best clinical response. The outcome is reported by the the number of patients that were IHC-positive (MGMT detected) or IHC-negative (MGMT not detected), and by best clinical response [ie, complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD)]. The outcome is reported as a number without dispersion. |
18 months
|
O6-methylguanine DNA Methyltransferase (MGMT) by Promoter Methylation
Time Frame: 18 months
|
O6-alkylguanine DNA alkyltransferase is a protein that in humans is encoded by the gene "O6-methylguanine DNA methyltransferase" (MGMT). Deficiency of the gene product, ie, the protein, is refered to as "MGMT deficiency," and is thought to be predictive of response to temozolomide and is more often associated with pancreatic NETs. MGMT status in pre-treatment biopsy specimens was to be assessed by extent of genetic promoter methylation (an analysis of DNA), and correlated to subject survival. MGMT status in pre-treatment biopsy specimens was to be assessed by promoter methylation assessment (PM), and associated to best clinical response. The outcome is reported by the the number of patients that were PM-positive (MGMT detected) or PM-negative (MGMT not detected), and by best clinical response [ie, complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD)]. The outcome is reported as a number without dispersion. |
18 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Shaheen Shagufta, MD, Stanford University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Disease Attributes
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Pancreatic Diseases
- Adenoma
- Carcinoma, Neuroendocrine
- Adenoma, Islet Cell
- Recurrence
- Pancreatic Neoplasms
- Neuroendocrine Tumors
- Carcinoma, Islet Cell
- Insulinoma
- Gastrinoma
- Glucagonoma
- Somatostatinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Antibodies
- Temozolomide
- Capecitabine
- Immunoglobulins
- Bevacizumab
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
Other Study ID Numbers
- IRB-22412
- 4593 (Other Identifier: superceded IRB number)
- NCI-2011-03497 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- SU-10282011-8571 (Other Identifier: Stanford University)
- NET0012 (Other Identifier: OnCore)
- END0012 (Other Identifier: superceded OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Pancreatic Cancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Gastric Cancer | Stage III Colon Cancer | Stage III Gastric Cancer | Stage III Rectal...United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Recurrent Colorectal Carcinoma | Unresectable Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Solid Neoplasm | Recurrent Solid Neoplasm | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes... and other collaboratorsCompletedUnresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Recurrent Colorectal Carcinoma | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic... and other conditionsUnited States
-
University of WashingtonCompletedAdvanced Malignant Solid Neoplasm | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Recurrent Malignant Solid Neoplasm | Stage IVA Pancreatic Cancer | Stage IVB Pancreatic Cancer | Bile Duct CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
National Cancer Institute (NCI)CompletedSorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerAdenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
National Cancer Institute (NCI)CompletedPancreatic Cancer | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic CancerCanada
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic CancerUnited States
Clinical Trials on Capecitabine
-
Sun Yat-sen UniversityChengdu Biostar PharmaceuticalsNot yet recruitingBreast Neoplasms | Locally Advanced or Metastatic Breast CancerChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Hoffmann-La RocheCompletedBreast Cancer, Colorectal CancerNew Zealand, Australia, United Kingdom
-
Samsung Medical CenterCompletedAdvanced or Recurrent Esophageal Squamous Cell CarcinomaKorea, Republic of
-
Fudan UniversityCompletedMetastatic Breast CancerChina
-
Binghe XuHoffmann-La RocheUnknownSkin Diseases | Neoplasms by Site | Breast Neoplasms | Breast Diseases | Neoplasm MetastasisChina
-
Cancer Institute and Hospital, Chinese Academy...Hoffmann-La RocheUnknownCarcinoma, Invasive Ductal, BreastChina
-
Jules Bordet InstituteCompletedBreast Cancer | Elderly PatientsBelgium
-
The First Affiliated Hospital of Zhengzhou UniversityRecruiting
-
Jiangxi Provincial Cancer HospitalNot yet recruitingNasopharyngeal Carcinoma | Maintenance Therapy | High-Risk Cancer